Changes of T-lymphocyte subsets in peripheral blood and liver function in patients with chronic severe hepatitis B after treatment with entecavir

Objective To investigate the changes of the serum T-lymphocyte subsets in peripheral blood and liver function in patients with chronic severe hepatitis B( CSHB) after treatment with entecavir. Methods Sixty patients with chronic severe hepatitis B were randomly divided into treatment group( n = 30) and control group( n = 30). The patients in both groups were treated by routine therapy,however,the patients in treatment group,on the basis of control group,were treated by entecavir for 24 weeks. The T lymphocyte subsets in peripheral blood and liver function were detected by flow cytometry before treatment and at 12th week and 24 week after treatment for both groups. Results After treatment the CD+4subset and the ratio of CD+4/CD+8in both groups were increased in different degrees,however,CD+8subset was decreased,as compared with that before treatment( P 0. 05),however,the changes in treatment group after treatment were more obvious than those in control group( P 0. 05). The parameters about liver function in both groups were improved,as compared with those before treatment,but the improvement degree in treatment group was more obvious than that in control group( P 0. 05).Conclusion Entecavir can obviously enhance cellular immune function and liver function of patients with chronic severe hepatitis B and can inhibit virus replication.